ABL Bio to Attend East-West Biopharma Summit

ABL Bio, a company specializing in bispecific antibodies, announced on March 5 that it will participate in the "5th East-West Biopharma Summit: Seoul," which will be held from March 9 to 11. This event is co-hosted by BioCentury, a global bio-specialized media outlet, and BayHelix, a network of biopharma executives, with the global consulting firm McKinsey & Company joining as an insight partner.

Sanghoon Lee, CEO of ABL Bio, is being interviewed by reporters during the 44th JP Morgan Healthcare Conference (JPMHC) held in San Francisco, California, USA, in January this year. Photo by Donghoon Jeong

원본보기 아이콘

The East-West Biopharma Summit serves as a platform for pharmaceutical and biopharma industry stakeholders to share insights on the global market and explore new business opportunities. Leading global companies such as Eli Lilly, Roche, Boehringer Ingelheim, MSD, and GSK are also scheduled to participate.

At this event, Sanghoon Lee, CEO of ABL Bio, will join the "Deal Maker Showcase" session as a panelist on March 10 and will share key strategies for successful technology transfer to global companies, as well as the lessons learned and mistakes made during negotiation processes.

In addition, ABL Bio plans to meet with global companies visiting Seoul for the event to discuss business development and seek various partnership opportunities. Currently, the technology attracting the most attention from global companies is the blood-brain barrier (BBB) shuttle platform known as "Grabody-B." In April last year, ABL Bio signed a technology transfer agreement for Grabody-B with GSK worth 2.1401 billion pounds (approximately KRW 4.1 trillion). In November of the same year, the company entered into a Grabody technology transfer agreement with Eli Lilly totaling USD 2.602 billion (approximately KRW 3.8 trillion), alongside a strategic equity investment agreement worth USD 15 million (approximately KRW 2.2 billion).

ABL Bio also plans to continue sharing clinical data for immuno-oncology drugs utilizing the 4-1BB-based bispecific antibody platform "Grabody-T." Recently, ABL111 (Givastomig), the fastest-developing pipeline based on Grabody-T, began Phase 2 clinical trials targeting patients receiving first-line treatment for metastatic gastric cancer. ABL Bio also aims to expand clinical trials of other Grabody-T-based pipelines from monotherapy to combination therapy.

Sanghoon Lee, CEO of ABL Bio, commented, "I am honored to be invited as a panelist for the Deal Maker Showcase at the East-West Biopharma Summit. I plan to share the experience and know-how gained through the technology transfer process," adding, "Business meetings with global companies are ongoing, and I expect a very busy schedule during the event. I will do my best to achieve good results."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.